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RAPID COMMUNICATION
Administration of Interleukin-15 Peptide Improves Cardiac
Function in a Mouse Model of Myocardial Infarction
Kurosh Ameri, PhD,* Dulguun Bayardorj, MS,* Raffi Samurkashian,† Maxwell Fredkin, BA,*
Eric Fuh, MD,‡ Vien Nguyen, PhD,* and Yerem Yeghiazarians, MD*
Abstract: Interleukin-15 is a pleotropic factor, capable of modu-
lating metabolism, survival, proliferation, and differentiation in
many different cell types. The rationale behind this study relates to
previous work demonstrating that IL-15 is a major factor present in
stem cell extracts, which protects cardiomyocytes subjected to
hypoxic stress in vitro. The objective of this current study was to
assess whether administration of IL-15 peptide will also show
protective effects in vivo. The data indicate that administration of
IL-15 reduces cell death, increases vascularity, decreases scar size,
and significantly improves left ventricular ejection fraction in
a mouse model of myocardial infarction.
Key Words: interleukin-15, myocardial infarction, cardiomyocyte,
ejection fraction, vascular
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INTRODUCTION
Several laboratories have demonstrated that stem cells
exert their beneficial therapeutic effects in the heart through
paracrine mechanisms.1–5 For example, mesenchymal stem
cells or bone marrow mononuclear cells can mediate cardio-
myocyte (CM) survival/cardioprotective effects through para-
crine factors.3,6,7 Of the many paracrine factors present in
stem cell extracts, individual ones, on their own, have shown
to account for some of the beneficial effects observed.8,9 Our
original work demonstrated that administration of bone mar-
row derived stem cell extract, in a mouse model of infarction
induced by permanent ligation of the left anterior descending
coronary artery (LAD), reduced CM death, decreased infarct
scar size, and improved vascularity and cardiac function.5
One of the factors highly present in the extract was the cyto-
kine interleukin-15 (IL-15), which protected CMs subjected
to hypoxic stress in vitro.10 In this article, we have assessed
whether IL-15 would also have protective effects in vivo by
using a LAD-infarction mouse model. The data demonstrate
that administration of IL-15 peptide in vivo improves left
ventricular ejection fraction (LVEF), which correlates with
diminished CM cell death and scar size as well as increased
vascularity.
METHODS
Animals and Study Groups
Ten- to 12-week-old male C57BL/6 mice were used for
all experiments and handled in accordance with the guidelines
of the Institutional Animal Care and Use Committee.
MI and Echocardiography
Details of the experimental techniques have been
reported previously.11 All analyses were performed blinded.
Animal Treatment and Control
Animals were randomized into 2 groups: IL-15 therapy
versus control. One-hundred microliter IL-15/saline solution or
100-mL 0.9% saline solution was injected every 6 hours intra-
peritoneally (IP) into experimental and control animals, respec-
tively, twice at the day of Myocardial infarction (MI) and 3
times at days 1 and 2 after MI. IL-15 level was evaluated from
blood serum 1 hour after IP injection. IP administration of 10-mg
IL-15 resulted in maximum levels in blood serum, and higher
doses of IL-15 (up to 40 mg) did not increase blood serum IL-15
level any more than the 10-mg dose. IL-15 was sustained up to 4
hours after each single injection. Animals were sacrificed at days
5 and 28 after MI heart tissues were embedded in paraffin.
Apical half of each heart was further analyzed. The treatment
procedure is presented in Figure 1A.
Tissue Analysis
Details of the tissue analysis techniques have been
reported previously.5 Briefly, tissue sections from the mid-
ventricular level were analyzed by Masson’s trichrome kit
(American MasterTech, KTMTR) and Image-Pro Plus 6.0
(MediaCybernetics) to detect infarct size. Cardiomyocytes
undergoing apoptosis were detected by 2 methods: TUNEL
assay using ApopTag Plus Peroxidase In Situ Apoptosis
Detection Kit (Milipore Sigma, S7101, Burlington, MA)
and colocalization of cleaved caspase-3 (Cell Signaling,
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9661S, 1:200) and cardiac troponin-I (Abcam 19615, 1:50,
Cambridge, United Kingdom). Secondary antibodies used
were Alexa Flour 546 (Invitrogen A-11035, Carlsbad, CA)
and 488 (Invitrogen, A-11001), respectively. Apoptotic CMs
were counted in 5 random high-power fields in each of 3
zones: infarct zone, peri-infarct zone (PZ), and remote zone.
Tissues were imaged using Olympus fluorescent microscope
at 20X. A maximum of 5 random high-power fields per each
zone was taken. All analyses were performed blinded.
Arteriole and Capillary Staining
For vessel staining, Rat Detection Kit for Anti-Mouse
CD31 from Biocare (CM303) was used.
In Vitro Angiogenesis Assay
Angiogenesis Starter Kit (Gibco A1460901) was used
to examine the effect of IL-15 on tube formation of human
umbilical vein endothelial cells (HUVECs). Briefly, passage-
2 HUVECs were cultured in large vessel endothelial supple-
ment (LVES)-supplemented Medium 200 (M200), and media
were changed every other day until the HUVECs reached
80% confluency. On the day of assay, 96-well plates (Corning
Inc, Corning, NY) were coated with Geltrex matrix. The
HUVECs were added to Geltrex matrix-coated plates at
density of 9000 cells/well and incubated for 7 hours. The
experimental conditions contained LVES-supplemented
M200 with IL-15 while the control contained only LVES-
supplemented M200. Tube formation was visualized with 2-
mM Calcein AM (Invitrogen C3099), and each well was
imaged using an inverted fluorescent Olympus microscope
with 4X objective and quantified using Angiogenesis Ana-
lyzer tool of Image J. The experiment was repeated 3 times.
All analyses were performed blinded.
Statistics
Statistical results were calculated based on Student’s t-
test. A P value below 0.05 was deemed as statistically sig-
nificant. Data error bars are presented as SEM.
RESULTS
IL-15 Treatment Improves Cardiac Function In
Vivo
To establish baseline heart function, C57BL/6 mice
were evaluated through echocardiography 1 day before
induction of MI (21 in Fig. 1A). After establishing the base-
line heart function, MI was induced in mice (day 0 in Fig. 1A)
and IL-15 (10 mg) or saline as control was administered
through IP injection into the animals twice (every 6 hours)
on the day of the MI and then 3x/d on days 1 and 2 after MI
(Fig. 1A). At days 1 and 28 after MI, mice were examined
through echocardiography (Fig. 1A). Echocardiography
showed no differences in ejection fraction (LVEF) and stroke
volume between treated and control groups 1 day after
FIGURE 1. Effect of IL-15 on left ventricular function and infarct size. A, MI was induced in C57BL/6 mice at day 0. IL-15 (10 mg)
or saline as control was administered through IP injection every 6 hours into the animals twice at the day of MI and 3 times on the
following days as indicated. B–C, Left ventricular function was evaluated by echocardiography on the day before MI (21) and at
days 1 and 28 after MI. B, IL-15 significantly improved LVEF. C, Stroke volume was significantly higher after IL-15 treatment. D, On
average, IL-15 treatment significantly reduced the infarct size by 1.7-fold. E, As indicated by Masson’s trichrome staining in the
representative figures, IL-15 treatment resulted significantly reduced infarct size compared with the saline-treated control.
IL-15, n = 28. saline, n = 26. *P , 0.05. Error bars are SEM.
IL-15 Improves Heart Function In VivoJ Cardiovasc Pharmacol  Volume 75, Number 1, January 2020
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.jcvp.org | 99
infarction (Figs. 1B, C). However, these parameters were
significantly improved 28 days after infarct with the IL-15–
treated group. These data indicate that IL-15 can improve
cardiac function after an infarct in a mouse of infarction.
We then questioned how the improved heart function would
correlate with infarct size. As indicated graphically in Figure
1D, and as a representative figure in 1E, IL-15–treated group
had significantly smaller infarct size as compared to control
mice 28 days after infarct.
IL-15 Treatment Reduces Cardiomyocyte Cell
Death
We then questioned whether decreased infarct size after
28 days is resultant of diminished cell death at an earlier time
point. Immunohistochemical analysis performed on heart
sections 5 days after MI indicated diminished cell death in
the PZ. We used immunohistochemistry and immunofluores-
cence techniques to specifically identify changes occurring in
CMs. At day 5, IL-15 treatment resulted in significantly lower
cleaved caspase-3 positive and TUNEL-positive CMs in the
PZ, indicating diminished apoptotic CMs (Figs. 2A–D). As
indicated graphically in Figure 2A, cleaved caspase 3-positive
CM count was diminished in IL-15–treated group. Figure 2B
indicates an example of colocalized cleaved caspase 3 with
troponin I that is indicative of CMs. As indicated graphically
in Figure 2C, less TUNEL-positive apoptotic CMs are evident
in the IL-15–treated group. Figure 2D shows examples of
TUNEL-positive CMs as observed microscopically. IL-15
has been previously shown to protect hypoxic CMs in vitro
attributed to the IL-15 receptor complex activating the
STAT3 and ERK1/2 pathway.10 Therefore, the effects of
IL-15 in reducing caspase-3 cleavage and TUNEL-positive
CMs, may be due to STAT3 and ERK1/2 signaling.
IL-15 Treatment Effects Vascularity
IL-15 has previously been reported to modulate angio-
genesis.12 Thus, we first examined the effect of IL-15 on
in vitro HUVEC angiogenesis assay (Figs. 3A, B). We incor-
porated IL-15 into HUVEC angiogenesis assays by adding
50-ng/mL IL-15 to the assay media and assessed the number
of nodes as well as the extend of tube formation. Figure 3A
shows examples of the HUVEC assay as observed microscop-
ically with and without IL-15. There was an increase in the
number of nodes, number of tubes, and tube length when IL-
15 was added (Fig. 3B). These results indicated that IL-15
could modulate angiogenesis in vitro. We next examined
FIGURE 2. Effect of IL-15 on cell death. A, IL-15 treatment significantly reduced cardiomyocyte (CM) death, as evaluated by
cleaved caspase-3 in PZ at day 5 after MI. B, Representative figure showing analysis of cleaved caspase as bright red stain co-
localizing with cardiomyocytes that were stained with troponin I. White arrows indicate cleaved caspase 3-positive CMs. C, TUNEL
assay at day 5 after MI also indicated diminished apoptotic CMs in PZ. D, Representative figure showing how apoptotic cells were
evaluated: MM-AP (pink tone) and DAB (brown tone) against cTnI and terminal deoxynucleotidyl transferase (TdT), respectively.
Nuclei were stained with hematoxylin. White arrows indicate apoptotic CMs. Zoomed in pictures show TUNEL-positive car-
diomyocytes. Yellow arrow shows an example of negative stain for TUNEL. IL-15, n = 28. saline, n = 26. IZ, infarct zone; PZ,
Peri-infarct zone. *P , 0.05. Error bars are SEM.
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whether IL-15 treated mice had increased vascularity (Figs.
3C, D). Indeed, IL-15 treatment significantly increased vessel
area density at the PZ 5 days after MI, as evaluated by CD31
staining. Figure 3C indicates vessels as observed microscop-
ically and graphically in Figure 3D.
DISCUSSION
This brief report provides evidence that IL-15 can
have cardioprotective effects in vivo. Several other stem
cell factors have been shown to regulate vasculariza-
tion3,7,13 or prevent the metabolic changes associated with
infarction and have survival effects on CMs.3,6,8,9,14 Sim-
ilarly, IL-15 can modulate cell death,15 metabolism,16 stem
cell differentiation,17 endoplasmic reticulum stress/
unfolded protein response,18 oxidative stress,19 and angio-
genesis,12 which are parameters affected by MI. Therefore,
it is highly likely that the effects of IL-15 on heart function
reported in this article are due to pleiotropic effects such as
modulating endoplasmic reticulum stress20,21 and glucose
uptake.22 IL-15 has been previously shown to protect hyp-
oxic CMs in vitro attributed to the STAT3 and ERK1/2
pathway.10 In addition, a characteristic of the ischemic
microenvironment is decreased levels of oxygen and glu-
cose deprivation, which can result in increased ROS and
DNA damage. Indeed, IL-15 has been shown to diminish
H2O2-mediated oxidative stress in skeletal muscle cells.19
Similarly, we observed a reduction in H2O2-mediated oxi-
dative stress with cardiac fibroblast in vitro when treated
with IL-15 (data not shown). Interestingly, deletion of
STAT3 can sensitize cells to oxidative stress, and hence,
the antioxidant effect of IL-15 may be due to STAT3 acti-
vation.23 Another target of IL-15, namely ERK1/2, may
additionally modify STAT3 phosphorylation (S727),
boosting the transcriptional activity of STAT3.24 Whether
activation of ERK1/2 through IL-15 occurs in cardiac cells
on treatment leading to STAT3 phosphorylation (S727)
needs to be investigated.
FIGURE 3. Effect of IL-15 on angiogenesis and cardiac vascularity. A, Representative images of HUVEC angiogenesis assay with
(+IL-15) and without IL-15 (control). B, Addition of IL-15 to the culture media of HUVECs resulted in significantly greater number
of nodes, tubes, and tube length compared with the control. C, Representative figure showing CD31 staining and visualization for
evaluating vessel density. D, Vessel area density was significantly increased in PZ with the IL-15–treated group. IL-15 n = 28;
saline, n = 26. *P , 0.05. Error bars are SEM. IZ, infarct zone; PZ, peri-infarct Zone.
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It should be also noted that in the setting of myocardial
infarction, an initial proinflammatory response plays a major
role in modulating repair in the infarcted region.
We do not rule out immune-modularity effects of IL-15
that could be beneficial for the infarcted heart in an acute
setting, such as suppressing B-cell activation for beneficial
purposes,25 modulating macrophages for reparative purpo-
ses,26 or Gr-1+ neutrophil subsets that may play important
repair roles.27 Indeed, IL-15 administration to mice did mod-
ulate markers associated with the aforementioned immune
cells (data not shown). However, prolonged IL-15 adminis-
tration may result in undesired inflammatory response, and
hence, we did not perform prolonged administration of IL-15.
It is encouraging that IL-15 shows some beneficial
effects in an in vivo infarction model; however, further
detailed in vivo work, including a wider ischemia model
spectrum, such as reperfusion models, is needed to assess for
any potential clinical benefits of IL-15 after an infarct. Our
laboratory is currently delineating the pleiotropic effects of
IL-15 for improving heart function after an infarct and
investigating IL-15 in additional mouse models to see
whether it has any therapeutic potential.
CONCLUSIONS
IL-15 peptide administration improves heart function
after an infarct in a mouse model of infarction.
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